Active targeting schemes for nanoparticle systems in cancer therapeutics.

By J. Byrne, Tania Betancourt, L. Brannon-Peppas. Advanced Drug Delivery Reviews, 2008

1,645 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/a40fcd1da9c1a9f5bd333c7fcb4ae0bb10d5fd08

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Biomedical Engineering

In Molecular Biology

Citations in the corpus

Strategies in the design of nanoparticles for therapeutic applications (2010, background): “Beyond these basic features of nanoparticle design, a multitude of approaches for targeting specific cellular populations or for altering the biodistribution of engineered nanoparticles in vivo are being develope”
Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy (2012, background): “Tumors also have a compound retention time higher than that of normal tissues because tumors lack a well-defined lymphatic system [15,16].”
Polymers for Drug Delivery Systems (2010, background): “Folate or biotin ligands enhance cellular uptake via receptor-mediated endocytosis (68), and TAT is a well-known peptide transduction domain (69).”
Nanoparticles in the clinic (2016, background): “Additionally, all of these formulations are passively targeted, with no active or chemicalbased targeting moieties; again, this is despite the proven advantages of active-targeting in preclinical settings.(25,26,38) It is likely that the other advantages, notably their reduced toxicity stemming from”
Cancer active targeting by nanoparticles: a comprehensive review of literature (2014, background): “The upregulation of transferrin receptors on metastatic and drug-resistant malignant cells (which may reach up to 100-fold higher than that in normal cells), the extracellular status of transferrin in the body and its internalization by cells make transferrin and transferrin mimicking agents suitabl”
Innovative approaches for cancer treatment: current perspectives and new challenges (2019, background): “Small ligands are cheap and can be linked to nanoparticles by simple conjugation chemistry [133, 134].”
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Therefore, the approach is aimed towards increasing interactions between NPs and cell and enhancing internalization of drugs without altering the overall biodistribution [6, 145, 146].”